文献速递妇科

质量改进研究:人乳头瘤病毒mRNA检测在识别潜伏性人乳头瘤病毒感染女性中缺乏可靠性

Quality Improvement to Demonstrate the Lack of Reliability of the Human Papillomavirus mRNA Assay to Identify Women With Latent Human Papillomavirus Infections.
PubMed 文献 · Obstet Gynecol · 2018-01-01

该质量改进研究利用病理实验室数据库2014年11月至2016年6月的数据,分析30岁及以上有既往HPV DNA阳性史的女性中HPV mRNA检测与HPV DNA检测结果的一致性及对随访筛查的潜在影响。结果显示HPV mRNA结果与既往HPV DNA阳性结果差异达69.3%,71.7%有一次既往高危HPV阳性结果的患者和60.0%有两次及以上既往高危HPV阳性结果的患者随访可能发生改变。作者结论认为HPV mRNA检测对潜伏性HPV感染的敏感性低于HPV DNA检测,不应作为宫颈癌初筛工具。

要点

  • HPV mRNA结果与既往HPV DNA阳性结果差异达69.3%。
  • 71.7%有一次既往高危HPV阳性结果者随访可能改变。
  • 60.0%有两次及以上既往高危HPV阳性结果者随访可能改变。

核心结论

  • HPV mRNA检测对潜伏性HPV感染的敏感性低于HPV DNA检测。
  • 基于这些数据及随访护理的潜在变化,HPV mRNA检测不应作为宫颈癌初筛工具。
  • 应记录所使用的HPV检测类型,任何HPV mRNA结果应由HPV DNA检测确认。

研究设计与样本

  • 质量改进研究,使用病理实验室软件数据库2014年11月至2016年6月的数据。
  • 纳入30岁及以上、有超过一次HPV阳性结果的女性患者,包括一次或多次HPV mRNA检测结果和一次或多次有记录的HPV DNA检测结果用于比较。
  • 共识别425份30岁及以上有既往高危HPV DNA检测阳性史的女性患者病历。
  • 同时记录既往相关细胞学和阴道镜组织病理学结果。
  • 使用美国妇产科医师学会(American College of Obstetricians and Gynecologists)宫颈癌筛查指南比较随访建议的潜在差异。

主要发现

  • HPV mRNA结果与既往HPV DNA阳性结果差异为69.3%。
  • 71.7%有一次既往高危HPV阳性结果的患者随访可能发生改变。
  • 60.0%有两次及以上既往高危HPV阳性结果的患者随访可能发生改变。
  • 共评估231份阴道镜报告,其中62份(26.8%)为异常阴道镜报告,包括45例低级别鳞状上皮内病变、15例高级别鳞状上皮内病变和2例癌症。
  • 25例(40.3%)异常阴道镜发现见于有至少两次既往HPV DNA阳性结果且当前mRNA检测报告为HPV阴性的患者。

关键数值与推荐

  • 美国妇产科医师学会宫颈癌筛查指南用于比较随访建议的潜在差异。
  • HPV mRNA结果与既往HPV DNA阳性结果差异为69.3%。
  • 一次既往高危HPV阳性结果者随访可能改变比例为71.7%。
  • 两次及以上既往高危HPV阳性结果者随访可能改变比例为60.0%。
  • 异常阴道镜报告62/231(26.8%),包括低级别鳞状上皮内病变45例、高级别鳞状上皮内病变15例、癌症2例。

临床怎么用

  • 作者认为HPV mRNA检测不应作为宫颈癌初筛工具。
  • 应记录所使用的HPV检测类型。
  • 任何HPV mRNA结果应由HPV DNA检测确认。
  • 许多病理实验室已转向使用HPV mRNA检测,但未与妇科医生就其对患者随访的影响进行明确讨论。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the consistency between human papillomavirus (HPV) mRNA testing in women with a history of previous HPV infections diagnosed by HPV DNA assay and the potential effects on follow-up HPV screening. METHODS: This was a quality improvement study that used data from a pathology laboratory software database reviewed from November 2014 to June 2016 to identify female patients aged 30 years or older with greater than one HPV-positive result, including one or more HPV mRNA assay results and one or more documented HPV DNA assay results for comparison. Previous correlative cytology and colposcopic histopathology were also documented. American College of Obstetricians and Gynecologists' cervical cancer screening guidelines were used to compare potential differences in follow-up recommendations. RESULTS: Four hundred twenty-five charts for female patients 30 years of age or older were identified with one or more prior high-risk HPV infections by DNA assay. There was a 69.3% difference in HPV mRNA results compared with previous HPV DNA-positive results. There was a potential change in follow-up for 71.7% of patients with one prior high-risk-HPV-positive result and 60.0% of patients with two or more prior high-risk HPV-positive results. There were 231 colposcopy reports evaluated in this study. Of these, 62 (26.8%) were abnormal colposcopy reports, including 45 low-grade squamous intraepithelial lesions, 15 high-grade squamous intraepithelial lesions, and two cancers. Twenty-five (40.3%) abnormal colposcopy findings were in patients with a history of at least than two prior HPV DNA-positive results and a report of currently being HPV-negative with the mRNA assay. CONCLUSION: The HPV mRNA assays are less sensitive for detection of latent HPV infections compared with HPV DNA assays. Based on these data and the potential change in follow-up care, the HPV mRNA assay should not be used for a primary screening tool for cervical cancer. Many pathology laboratories have shifted to using the HPV mRNA assay without clear discussion with gynecologists about the effects on patient follow-up. The type of HPV assay being used should be documented and any HPV mRNA result confirmed by HPV DNA assay.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Cotton S, Brown RE, Nugent EK, et al. Quality Improvement to Demonstrate the Lack of Reliability of the Human Papillomavirus mRNA Assay to Identify Women With Latent Human Papillomavirus Infections. Obstet Gynecol. 2018. PMID: 29528922. doi:10.1097/AOG.0000000000002530

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。